Wu T Y, Fleischmann W R
Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston 77555, USA.
J Interferon Cytokine Res. 1998 Oct;18(10):829-39. doi: 10.1089/jir.1998.18.829.
B16 melanoma cells exposed to >2 weeks of in vitro interferon-alpha (IFN-alpha) treatment (B16alpha cells) were UV inactivated and used for vaccination. This vaccination was efficacious against challenge with parental B16 cells in the absence of adjuvant therapy. Vaccinations based on parental cells and B16 cells exposed to short-term in vitro IFN-alpha treatment were not effective. The efficacy of B16alpha vaccination was evaluated using three B16 tumor models. Using intraperitoneal (i.p.) tumor challenge given after vaccination, vaccination efficacy depended on the concentration of IFN-alpha to which B16alpha cells were exposed, the number of inactivated B16alpha cells inoculated, the number of inoculations administered, and the amount of tumor burden. A significant fraction (30%) of vaccinated mice surviving initial challenge had durable immunity against a second parental tumor challenge. This immunity increased to 92% with administration of a single booster vaccination. Using metastatic tumor challenge given after vaccination, vaccination reduced lung metastases by approximately 67%. Using vaccination begun 3 days after subcutaneous (s.c.) tumor challenge, regression of established tumor occurred when vaccination was given i.p. (39%) or contralaterally s.c. (53%). Taken together, the results suggest that vaccination with inactivated B16alpha cells may serve as a model for induction of host tumor immunity against primary or secondary tumors.
暴露于体外干扰素-α（IFN-α）治疗超过2周的B16黑色素瘤细胞（B16α细胞）经紫外线灭活后用于疫苗接种。在没有辅助治疗的情况下，这种疫苗接种对亲本B16细胞的攻击有效。基于亲本细胞和暴露于短期体外IFN-α治疗的B16细胞的疫苗接种无效。使用三种B16肿瘤模型评估了B16α疫苗接种的效果。通过接种后给予腹腔内（i.p.）肿瘤攻击，疫苗接种效果取决于B16α细胞所暴露的IFN-α浓度、接种的灭活B16α细胞数量、接种次数以及肿瘤负荷量。在初次攻击后存活的接种疫苗小鼠中有很大一部分（30%）对第二次亲本肿瘤攻击具有持久免疫力。单次加强疫苗接种后，这种免疫力提高到了92%。通过接种后给予转移性肿瘤攻击，疫苗接种使肺转移减少了约67%。在皮下（s.c.）肿瘤攻击3天后开始接种疫苗，当通过腹腔内（39%）或对侧皮下（53%）接种疫苗时，已建立的肿瘤会发生消退。综上所述，结果表明用灭活的B16α细胞进行疫苗接种可能作为诱导宿主针对原发性或继发性肿瘤的肿瘤免疫的模型。
